Investing in the Swiss Market Index (SMI) carries several specific risks, primarily related to market concentration and currency exposure. Because the index comprises only twenty blue-chip companies and is heavily dominated by massive multinational healthcare and pharmaceutical giants like Nestlé, Novartis, and Roche, poor performance or regulatory headwinds in those specific sectors can disproportionately drag down the entire index. Additionally, international investors face foreign exchange risk, as fluctuations in the Swiss Franc relative to their home currency can significantly impact overall dollar-denominated investment returns.